Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oscient To Market Antara Using 280-Person Primary Care Sales Force

This article was originally published in The Pink Sheet Daily

Executive Summary

Oscient acquired the U.S. rights to the fenofibrate drug from Reliant for $78 mil.

You may also be interested in...



Reliant Submits Response To FDA For Expanded Omacor Indication

Company seeks an indication for the omega-3 ester to treat high triglycerides as an adjunct to diet and statin therapy.

Reliant Submits Response To FDA For Expanded Omacor Indication

Company seeks an indication for the omega-3 ester to treat high triglycerides as an adjunct to diet and statin therapy.

Reliant Launches Omacor With Existing Sales Force

Reliant had hoped to hire 200 additional reps to support launch of the omega-3 product, which was approved in 2004.

Topics

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel